{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T20:34:48Z","timestamp":1767731688969,"version":"build-2238731810"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0074216","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T23:53:17Z","timestamp":1380585197000},"page":"e74216","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil\/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles"],"prefix":"10.1371","volume":"8","author":[{"given":"Nelly","family":"Mezzaroba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Zorzet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Secco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Tripodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramiro","family":"Mendoza-Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Capolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Granzotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Spretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Lucaf\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Mansilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Garrovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo H.","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Baj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Pozzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Macor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"key":"ref1","unstructured":"IARC (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue; S. Swerdlow EC, N. Lee Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, editor. Lyon."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/path.2807","article-title":"The molecular background of aggressive B cell lymphomas as a basis for targeted therapy","volume":"223","author":"D de Jong","year":"2011","journal-title":"J Pathol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and chronic lymphocytic leukemia: a decade later","volume":"118","author":"F Malavasi","year":"2011","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt's lymphoma","volume":"379","author":"EM Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00262-005-0010-0","article-title":"Monoclonal antibody therapy of chronic lymphocytic leukemia","volume":"55","author":"BD Cheson","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"ref6","unstructured":"McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12: 1763\u20131769; discussion 1769\u20131770, 1775\u20131767."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"L Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"GM Mead","year":"2008","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/jnai.2011.2414","article-title":"P53 and microRNAs in chronic lymphocytic leukemia","volume":"2","author":"J Bloehdorn","year":"2010","journal-title":"Journal of Nucleic Acids Investigation volume"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","article-title":"Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival","volume":"113","author":"NA Johnson","year":"2009","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10059-011-0051-5","article-title":"Nanomaterials for cancer therapy and imaging","volume":"31","author":"KH Bae","year":"2011","journal-title":"Mol Cells"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"ME Davis","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"R Duncan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.addr.2007.06.003","article-title":"Biodegradable nanoparticles for cytosolic delivery of therapeutics","volume":"59","author":"JK Vasir","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2217\/17435889.3.3.367","article-title":"Micro\/nanostructured polymeric systems for biomedical and pharmaceutical applications","volume":"3","author":"F Chiellini","year":"2008","journal-title":"Nanomedicine (Lond)"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/17435889.1.3.297","article-title":"New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?","volume":"1","author":"SS Feng","year":"2006","journal-title":"Nanomedicine (Lond)"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1016\/S0142-9612(08)00562-0","article-title":"Nanoparticles of biodegradable polymers for cancer treatment","volume":"29","author":"SS Feng","year":"2008","journal-title":"Biomaterials"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/10611860701794353","article-title":"Polymeric nanoparticles for cancer therapy","volume":"16","author":"S Parveen","year":"2008","journal-title":"J Drug Target"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/17435889.2.5.669","article-title":"Biodegradable, polymeric nanoparticle delivery systems for cancer therapy","volume":"2","author":"EM Pridgen","year":"2007","journal-title":"Nanomedicine (Lond)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1083\/jcb.200910104","article-title":"Targeting of drugs and nanoparticles to tumors","volume":"188","author":"E Ruoslahti","year":"2010","journal-title":"J Cell Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"D Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2010-03-274258","article-title":"Nanoparticle-induced vascular blockade in human prostate cancer","volume":"116","author":"L Agemy","year":"2010","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1016\/j.biomaterials.2009.07.008","article-title":"Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy","volume":"30","author":"S Acharya","year":"2009","journal-title":"Biomaterials"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2010.08.005","article-title":"Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8","volume":"399","author":"A Bicho","year":"2010","journal-title":"Int J Pharm"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/157488410793352058","article-title":"Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human\/mouse model of Burkitt lymphoma","volume":"5","author":"GH Marin","year":"2010","journal-title":"Curr Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2310\/7290.2008.00028","article-title":"In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging","volume":"7","author":"S Biffi","year":"2008","journal-title":"Mol Imaging"},{"key":"ref27","first-page":"510","article-title":"Uptake of human eosinophil peroxidase by human neutrophils","volume":"124","author":"G Zabucchi","year":"1986","journal-title":"Am J Pathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e13720","DOI":"10.1371\/journal.pone.0013720","article-title":"Interaction of the retinoblastoma protein with Orc1 and its recruitment to human origins of DNA replication","volume":"5","author":"R Mendoza-Maldonado","year":"2010","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","article-title":"In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab","volume":"67","author":"P Macor","year":"2007","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2011-12-400184","article-title":"ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol","volume":"120","author":"E Mahoney","year":"2010","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ncb1007-1102","article-title":"Autophagosome formation: core machinery and adaptations","volume":"9","author":"Z Xie","year":"2007","journal-title":"Nat Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/eji.200425920","article-title":"Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59","volume":"35","author":"F Ziller","year":"2005","journal-title":"Eur J Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/blood-2002-08-2512","article-title":"Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents","volume":"101","author":"Y Zhou","year":"2003","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00002512-200016010-00002","article-title":"Management of chronic lymphocytic leukaemia","volume":"16","author":"N Kalil","year":"2000","journal-title":"Drugs Aging"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"RK Amaravadi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/cbr.2009.0655","article-title":"The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro","volume":"25","author":"E Mansilla","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/10428190290021506","article-title":"Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2\/bax\/ratio","volume":"43","author":"L Lagneaux","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/CAD.0b013e32832f4e50","article-title":"Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells","volume":"20","author":"R Rahim","year":"2009","journal-title":"Anticancer Drugs"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1078-0432.CCR-10-2572","article-title":"Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway","volume":"17","author":"G Zauli","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"J Golay","year":"2000","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/138945010790711950","article-title":"Cyclin-dependent kinase inhibitors as anticancer drugs","volume":"11","author":"V Krystof","year":"2010","journal-title":"Curr Drug Targets"},{"key":"ref42","first-page":"2927","article-title":"Hydroxychloroquine neuromyotoxicity","volume":"27","author":"M Stein","year":"2000","journal-title":"J Rheumatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08820530802049962","article-title":"Ocular toxicity of hydroxychloroquine","volume":"23","author":"R Tehrani","year":"2008","journal-title":"Semin Ophthalmol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/jps.21970","article-title":"Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery","volume":"99","author":"DA Rao","year":"2010","journal-title":"J Pharm Sci"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nmat2202","article-title":"Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles","volume":"7","author":"A Verma","year":"2008","journal-title":"Nat Mater"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2216","article-title":"Pathways of clathrin-independent endocytosis","volume":"8","author":"S Mayor","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biomaterials.2012.09.029","article-title":"Internalization pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles","volume":"34","author":"W Rima","year":"2013","journal-title":"Biomaterials"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1158\/0008-5472.CAN-11-0940","article-title":"Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells","volume":"71","author":"Y Li","year":"2011","journal-title":"Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"ME Reff","year":"1994","journal-title":"Blood"},{"key":"ref50","first-page":"176","article-title":"The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes","volume":"91","author":"J Golay","year":"2006","journal-title":"Haematologica"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"N Di Gaetano","year":"2003","journal-title":"J Immunol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2007.04.014","article-title":"Complement as effector system in cancer immunotherapy","volume":"111","author":"P Macor","year":"2007","journal-title":"Immunol Lett"},{"key":"ref53","first-page":"1002","article-title":"Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2","volume":"88","author":"J Golay","year":"2003","journal-title":"Haematologica"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"B Bellosillo","year":"2001","journal-title":"Blood"},{"key":"ref55","first-page":"1508","article-title":"Adult Burkitt lymphoma: advances in diagnosis and treatment","volume":"22","author":"IT Aldoss","year":"2008","journal-title":"Oncology (Williston Park)"}],"updated-by":[{"DOI":"10.1371\/annotation\/55af21b1-e916-4928-bba3-bf76a7abfc9d","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0074216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T23:13:31Z","timestamp":1596582811000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0074216"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0074216","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}